$4.78
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,300 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
Country

CA

CEO

Mr. Thomas Appio

IPO date

1994

Employees

20,300

ISIN

CA0717341071

Key stats

Open

$4.70

Volume

1.55M

Market cap

$2.60B

Prev. close

$4.86

Impl / hst vl

-

Open interest

$0.00

$4.70

Day’s Range

$4.90

$4.57

52W Range

$8.00

Valuation

38
Valuation score
Overvalued
P/E
-
P/S
0.17
P/B
-
Current ratio
1.32
Debt / Equity
-
ROE
-
Gross margin
70.76%
Income growth
1,170.54%
FCF growth
-79.40

Analysts estimates

Consensus rating
Hold

The average rating from top 4 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$6.46
The top 2 analysts forecasts that 12-month price may increase by 35.19%, with a low of $6.40 and a high of $6.65
$6.40
Low
$6.46
Avg
$6.65
High
Current price

Earnings

Q1 ‘26 revenue
$2.52B
Q1 ‘26 net income
-$1.42B
Revenue
Net income
Previous EPS
$0.78
Estimate EPS
$1.08
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply